Radiology and Imaging Specialists’ Post

OmniPathology's OmniPrism workflow revolutionizes GYN Pathology with a comprehensive approach that enhances early cancer detection and supports informed follow-up decisions. We go beyond traditional methods to tackle complex pathology questions. Discover our advanced techniques: https://bit.ly/41rMwRQ

Now you see me, now you don't! Dynamic imaging on extended field-of-view PET/CT scanners, like our Siemens Biograph Vision Quadra at the Melbourne Theranostic Innovation Centre, can identify nodes close to the ureter before urinary activity appears in the ureters and that can be obscured by retained urinary activity on delayed PSMA PET/CT imaging performed for staging and biochemical recurrence of prostate cancer. Yes, further delayed imaging following diuretic can unmask these nodes, providing the ureters clear, but this is less convenient for patients and departmental workflows. Later imaging is, however, useful for identifying small nodes close to vessels, that are most apparent on dynamic imaging but also provide an anatomical template of pelvic vasculature. We are still working on protocols to optimise how and when we do dynamic imaging, use pharmacologic interventions, and how to best extract the information that is available from list-mode acquisition. While this provides incredible flexibility, it also demands challenging choices on how information is reformatted. I doubt we have it perfected yet but we are determined to work it out for the benefit of our patients. “When you cease doubting, you have stopped moving forward.” -      Paulo Coelho, from “Brida”

Exciting potential lies in PET/CT dynamic imaging, offering a deeper understanding of physiological processes and advancing diagnostic capabilities. #PETCT #DynamicImaging

Building the future of minimally invasive medicine. The RAYDIAX TACT system is not just another CT scanner; it is a breakthrough technology designed for the interventional room. By reducing radiation exposure and enabling 2D/3D hybrid image, we make interventional procedures safer for both patients and clinicians. More importantly, real-time imaging gives doctors the control and precision they have been waiting for to manage previously difficult to treat or even untreatable tumors with confidence. This is the future of minimally invasive cancer treatment, and RAYDIAX is part of it. Learn more at Raydiax.com. #CancerTherapies #MedicalInnovation #CTTechnology #HealthTech

https://lnkd.in/da3H_Z-k Tired of stressing whether a brain tumor is progressing? Wish you had some insurance about calling tumor recurrence? Here’s the cheat sheet you NEED for the best signs of tumor progression! Read on for the newest @theAJNR SCANtastic on tumor imaging: https://lnkd.in/dg_HGin5 Tumor progression is like tumor escaping treatment. Just when treatment thinks it’s got tumor trapped at cliff, tumor is able to get away Think how you would get away if you were chased to a cliff’s edge---these are same signs of tumor progression: Jump off into the water: Tumor heads to the water—the ventricular surface Subependymal enhancement is very specific (93% sensitivity), but it isn’t commonly seen (38% sensitive). Cross over the rickety bridge: Tumor crosses over the brain’s main bridge: the corpus callosum Callosal involvement is only significant if combined w/multiple foci or crossing midline. Slide down the rocks: Spectroscopy looks like a slide down: Increased choline is seen w/recurrence—when combined w/low NAA, it looks like a reverse Hunter’s angle Increased Cho/NAA or Cho/Cre ratios can suggest recurrence Run fast & get your red blood hot: Blood volume is hot on perfusion: high rCBV on perfusion rCBV hotter than the normal contralateral white matter can be used as a gestalt Quantitatively, rCBV >1.75 is high suggestive of tumor & rCBV > 1.0 is concerning Try to sneak away when it’s dark: Tumor looks dark: Low ADC value (dark on T2) is concerning for tumor Quantitatively ADC value ≤ 1220 × 10-6 mm2/s is 74% sensitive & 89% specific I joke, “If the ADC is less than 1000 x 10-6, I am 1000% sure it’s tumor!” Now you know the best signs of tumor recurrence on imaging! Hopefully now you know when tumor progression should make your impression!

Unveiling the JNET classification - it's a game-changer for endoscopy diagnosis of colorectal neoplasms. For a quick overview: - Type 1: The chameleon type. Invisible vessel pattern, mimics normal mucosa surface pattern. - Type 2A: The consistent type. Regular vessel and surface patterns. High predictability. - Type 2B: The puzzling type. Irregular vessel and/or surface patterns. Uneven terrain. - Type 3: The warning sign. Clear demarcated area of submucosal invasive cancer.

Our research and others have demonstrated that treatment can reduce the amount of DNA obtained from tumour samples, which in turn limits the success rates of molecular testing for women who have been diagnosed with ovarian cancer. To tackle this issue, we have collaborated with our patients group and the DEMO team ( https://lnkd.in/eev2gm-6) to create a series of videos that explain the role of genetic testing for ovarian cancer patients. More recently, we have produced a video that provides a clear explanation of the ultrasound-guided biopsy procedure, including how to prepare for the test, how it is performed, what to expect during the procedure, and what to expect afterwards. This video has the potential to inspire more people to opt for tumour genetic testing, including whole-genome sequencing, which can offer crucial insights to those affected by ovarian cancer. https://lnkd.in/e-RNkCZK

The sensitivity of white light imaging (WLI) for detecting early gastric cancer (EGC) is not satisfactory ¹. Narrow band imaging (NBI) endoscopy is an innovative optical image-enhanced technology that better visualizes surface structures and blood vessels than does WLI ¹. With X1 Latest 4k Technology Endoscopy which is equipped with latest generation NBI helps our HCP'S in detection of early gastric cancers in their routine endoscopy which is much more accurate and precise with Extended Depth of Field . OLYMPUS - TRUE TO LIFE

The CBCT device includes a 3D biopsy feature that takes around 15 minutes on average. "Overcoming breast compression is made possible by CBCT's comfortable imaging technology". Early detection is crucial for breast cancer - and the latest innovations in medical technology are making it safer and more effective than ever before. The #KoningBreast3Dimaging #medicaldevice from #EuronoxxMedicalGroup is a game-changer in the #fightagainstbrestcancer (devastating disease). Koning Vera Breast 3D Imaging Scanner has "NO Compression, NO Pain", "True Isotropic 3D Image", "Safe & Low Effects of Radiation", "Fast Scan Time of only 7 Seconds", etc. Unlike traditional mammograms, the #KoningBreast3Dimaging uses a lower dose of radiation, making it a safer option for patients. And with its ability to better evaluate breast tissue, it can lead to earlier detection and more successful treatment outcomes. Don't wait until it's too late. Order the Koning Vera Breast 3D imaging device from Euronoxx Medical Group today and give your patients the best possible chance at beating breast cancer. Early detection is key - so take action now and experience the power of this cutting-edge technology. Visit at: https://lnkd.in/gWmx-3gj

🔬 New Poster on AI Auto-Contouring in Gynecological Brachytherapy! We're excited to share the work of Douglas Hoover, John Patrick, Nadith Ranasinghe, Jason Vickress, and the team at Western University, Verspeeten Family Cancer Centre. Their research on AI auto-contouring in gynecological brachytherapy highlights some promising results: High Geometric Accuracy: Limbus AI contours for the bladder showed a DSC of 0.87 ± 0.07, which is comparable to clinician contours with a DSC of 0.88 ± 0.03. Improved Inter-Observer Variability: AI-generated contours for the rectum (DSC of 0.77 ± 0.09) outperformed clinician variability (DSC of 0.64 ± 0.20), suggesting better consistency. Reliable Dosimetric Results: The mean unsigned D2cc dose differences were similar between AI and clinician contours, ensuring accurate treatment planning. To dive deeper into the impact of AI contouring, join our upcoming webinar: "Impact of AI Contouring for GYN Brachytherapy, Limbus Contour V1.8 New Models" on Wednesday, August 28th at 5:30 pm BST. Register Here: https://bit.ly/4ftabrW Disclaimer: Product not available in all markets. Pending regulatory/market clearances. https://lnkd.in/gRFdbqJC